Historical Stock Chart
3 Months : From Jan 2020 to Apr 2020
By Ian Walker
AstraZeneca PLC (AZN.LN) said Monday that it will take back the global rights to brazikumab after ending a license deal with Allergan PLC (AGN).
AstraZeneca said Allergen will fund the costs of developing brazikumab, which is used for Crohn's disease and ulcerative colitis.
The transaction is expected to complete in the first quarter of this year, subject to regulatory approvals associated with AbbVie Inc.'s (ABBV) proposed acquisition of Allergan, AstraZeneca said.
Write to Ian Walker at firstname.lastname@example.org
(END) Dow Jones Newswires
January 27, 2020 02:33 ET (07:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.